Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study.

Gantner P, Sylla B, Morand-Joubert L, Frange P, Lacombe K, Khuong MA, Duvivier C, Launay O, Karmochkine M, Arvieux C, Ménard A, Piroth L, Canestri A, Trias D, Peytavin G, Landman R, Ghosn J; Coferal-IMEA048 Study Group.

PLoS One. 2019 Apr 24;14(4):e0216010. doi: 10.1371/journal.pone.0216010. eCollection 2019.

2.

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.

Gantner P, Cotte L, Allavena C, Bani-Sadr F, Huleux T, Duvivier C, Valantin MA, Jacomet C, Joly V, Chéret A, Pugliese P, Delobel P, Cabié A, Rey D; Dat’AIDS Study Group.

PLoS One. 2019 Apr 18;14(4):e0215464. doi: 10.1371/journal.pone.0215464. eCollection 2019.

3.

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort.

Lions C, Cabras O, Cotte L, Huleux T, Gagneux-Brugnon A, Makinson A, Cabié A, Bonnet B, Duvivier C, Hocqueloux L, Cua E, Cheret A, Hustache-Mathieu L, Obry-Roguet V, Jacomet C, Poizot-Martin I; DAT’AIDS STUDY GROUP.

BMC Infect Dis. 2019 Mar 25;19(1):278. doi: 10.1186/s12879-019-3915-5.

4.

γδ T-cell subsets in HIV controllers: potential role of Tγδ17 cells in the regulation of chronic immune activation.

Chevalier MF, Bhatnagar N, Didier C, Lopez-Gonzalez M, Pavie J, Bollens D, Duvivier C, Collias L, Jung C, Scott-Algara D, Girard PM, Weiss L; ANRS EP56 group.

AIDS. 2019 Jul 1;33(8):1283-1292. doi: 10.1097/QAD.0000000000002196.

PMID:
30870199
5.

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.

Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, Valantin MA, Poizot-Martin I, Simon A, Rosenthal E, Lacombe K, Pialoux G, Bouchaud O, Gervais-Hasenknoff A, Goujard C, Piroth L, Zucman D, Dominguez S, Raffi F, Alric L, Bani-Sadr F, Lascoux-Combe C, Garipuy D, Miailhes P, Vittecoq D, Duvivier C, Aumaître H, Neau D, Morlat P, Dabis F, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

PLoS One. 2019 Jan 25;14(1):e0211286. doi: 10.1371/journal.pone.0211286. eCollection 2019.

6.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.

Billa O, Chalouni M, Salmon D, Poizot-Martin I, Gilbert C, Katlama C, Neau D, Chas J, Morlat P, Lacombe K, Naqvi A, Barange K, Gervais A, Bouchaud O, Rosenthal E, Lascoux-Combe C, Garipuy D, Alric L, Dominguez S, Vittecoq D, Goujard C, Duvivier C, Aumaitre H, Miailhes P, Zucman D, Simon A, Lazaro E, Raffi F, Esterle L, Wittkop L, Bani-Sadr F; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Dec 18;13(12):e0208657. doi: 10.1371/journal.pone.0208657. eCollection 2018.

7.

Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4).

Costagliola D, Potard V, Lang S, Abgrall S, Duvivier C, Fischer H, Joly V, Lacombe JM, Valantin MA, Mary-Krause M, Rozenberg S.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):214-223. doi: 10.1097/QAI.0000000000001903.

8.

A Calibration Device to Compare Body Plethysmographs Among Pediatric Lung Function Laboratories.

Demoulin B, Ioan I, Duvivier C, Bonabel C, Schweitzer C, Marchal F, Demoulin-Alexikova S.

Front Physiol. 2018 Oct 9;9:1408. doi: 10.3389/fphys.2018.01408. eCollection 2018.

9.

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients.

Allavena C, Hanf M, Rey D, Duvivier C, BaniSadr F, Poizot-Martin I, Jacomet C, Pugliese P, Delobel P, Katlama C, Joly V, Chidiac C, Dournon N, Merrien D, May T, Reynes J, Gagneux-Brunon A, Chirouze C, Huleux T, Cabié A, Raffi F; Dat’AIDS study group.

PLoS One. 2018 Sep 21;13(9):e0203895. doi: 10.1371/journal.pone.0203895. eCollection 2018.

10.

Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort.

Pelchen-Matthews A, Ryom L, Borges ÁH, Edwards S, Duvivier C, Stephan C, Sambatakou H, Maciejewska K, Portu JJ, Weber J, Degen O, Calmy A, Reikvam DH, Jevtovic D, Wiese L, Smidt J, Smiatacz T, Hassoun G, Kuznetsova A, Clotet B, Lundgren J, Mocroft A; EuroSIDA study.

AIDS. 2018 Oct 23;32(16):2405-2416. doi: 10.1097/QAD.0000000000001967.

PMID:
30134296
11.

Calendar trends in sexual behaviours in a cohort of HIV-infected MSM at the era of treatment as prevention of HIV infection.

Champenois K, Seng R, Persoz A, Essat A, Gaud C, Laureillard D, Robineau O, Duvivier C, Yazdanpanah Y, Goujard C, Meyer L; ANRS PRIMO cohort study group.

AIDS. 2018 Aug 24;32(13):1871-1879. doi: 10.1097/QAD.0000000000001916.

PMID:
29927787
12.

Factors associated with deaths from suicide in a French nationwide HIV-infected cohort.

Hentzien M, Cabie A, Pugliese P, Billaud É, Poizot-Martin I, Duvivier C, Valantin MA, Kaladjian A, Dramé M, Bani-Sadr F; Dat'AIDS Study Group.

HIV Med. 2018 Jun 1. doi: 10.1111/hiv.12633. [Epub ahead of print]

PMID:
29856132
13.

Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV.

Pradat P, Huleux T, Raffi F, Delobel P, Valantin MA, Poizot-Martin I, Pugliese P, Reynes J, Rey D, Hoen B, Cabie A, Bani-Sadr F, Cheret A, Duvivier C, Jacomet C, Fresard A, Hustache-Mathieu L, Cotte L; Dat’AIDS study Group.

AIDS. 2018 May 15;32(8):1077-1082. doi: 10.1097/QAD.0000000000001789.

PMID:
29438195
14.

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe.

Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren JD; EuroSIDA study group.

HIV Med. 2018 May;19(5):324-338. doi: 10.1111/hiv.12581. Epub 2018 Feb 1.

PMID:
29388732
15.

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.

Mercié P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, Duvivier C, Reynes J, Wirth N, Moinot L, Bénard A, Zucman D, Duval X, Molina JM, Spire B, Fagard C, Chêne G; ANRS 144 Inter-ACTIV study group.

Lancet HIV. 2018 Mar;5(3):e126-e135. doi: 10.1016/S2352-3018(18)30002-X. Epub 2018 Jan 9.

PMID:
29329763
16.

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination.

Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat’AIDS Study Group.

BMC Med. 2017 Dec 18;15(1):217. doi: 10.1186/s12916-017-0979-1.

17.

Hospitalization of HIV positive patients: Significant demand affecting all hospital sectors.

Seng R, Mutuon P, Riou J, Duvivier C, Weiss L, Lelievre JD, Meyer L, Vittecoq D, Zak Dit Zbar O, Frenkiel J, Frank-Soltysiak M, Boue F, Rapp C, Sobel A, Brucker G, Goujard C, Salmon D; COREVIH.

Rev Epidemiol Sante Publique. 2018 Feb;66(1):7-17. doi: 10.1016/j.respe.2017.08.002. Epub 2017 Dec 10.

PMID:
29233572
18.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group.

J Antimicrob Chemother. 2017 Dec 1;72(12):3502. doi: 10.1093/jac/dkx383. No abstract available.

PMID:
29121210
19.

Potential Role of Vδ2+ γδ T Cells in Regulation of Immune Activation in Primary HIV Infection.

Bhatnagar N, Girard PM, Lopez-Gonzalez M, Didier C, Collias L, Jung C, Bollens D, Duvivier C, Von Platen C, Scott-Algara D, Weiss L; ANRS EP-56 Group.

Front Immunol. 2017 Sep 25;8:1189. doi: 10.3389/fimmu.2017.01189. eCollection 2017.

20.

Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.

Lê MP, Belarbi L, Chaix ML, Dulioust E, Mahjoub N, Salmon D, Viard JP, Duvivier C, Peytavin G, Launay O, Ghosn J.

J Antimicrob Chemother. 2017 Nov 1;72(11):3167-3171. doi: 10.1093/jac/dkx275.

PMID:
28961979
21.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group.

J Antimicrob Chemother. 2017 Dec 1;72(12):3425-3434. doi: 10.1093/jac/dkx300. Erratum in: J Antimicrob Chemother. 2017 Dec 1;72(12):3502.

PMID:
28961719
22.

Detectable HIV-RNA in semen of HIV controllers.

Chaix ML, Boufassa F, Meyzer C, Leruez-Ville M, Mahjoub N, Nere ML, Genet P, Duvivier C, Lascoux-Combes C, Lambotte O, Ghosn J.

PLoS One. 2017 Aug 16;12(8):e0183376. doi: 10.1371/journal.pone.0183376. eCollection 2017.

23.

Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?

Pradat P, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat'AIDS study Group.

J Infect. 2017 Sep;75(3):234-241. doi: 10.1016/j.jinf.2017.05.008. Epub 2017 Jun 2.

PMID:
28579302
24.

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.

Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, Carrieri P, Chas J, Poizot-Martin I, Gervais A, Dominguez S, Neau D, Zucman D, Billaud E, Morlat P, Aumaitre H, Lascoux-Combe C, Simon A, Bouchaud O, Teicher E, Bani-Sadr F, Alric L, Vittecoq D, Boué F, Duvivier C, Valantin MA, Esterle L, Dabis F, Sogni P, Salmon D; ANRS CO13 HEPAVIH study group.

J Hepatol. 2017 Jul;67(1):23-31. doi: 10.1016/j.jhep.2017.02.012. Epub 2017 Feb 22.

PMID:
28235612
25.

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.

Cotte L, Ferry T, Pugliese P, Valantin MA, Allavena C, Cabié A, Poizot-Martin I, Rey D, Duvivier C, Cheret A, Dellamonica P, Pradat P, Parienti JJ; Dat’AIDS study group.

PLoS One. 2017 Feb 2;12(2):e0170661. doi: 10.1371/journal.pone.0170661. eCollection 2017.

26.

CMV+ Serostatus Associates Negatively with CD4:CD8 Ratio Normalization in Controlled HIV-Infected Patients on cART.

Poizot-Martin I, Allavena C, Duvivier C, Cano CE, Guillouet de Salvador F, Rey D, Dellamonica P, Cuzin L, Cheret A, Hoen B; Dat'AIDS Study Group.

PLoS One. 2016 Nov 8;11(11):e0165774. doi: 10.1371/journal.pone.0165774. eCollection 2016.

27.

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.

Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura V, Falconer K, Maltez F, Beniowski M, Vullo V, Hassoun G, Kuzovatova E, Szlavik J, Kuznetsova A, Stellbrink HJ, Duvivier C, Edwards S, Laut K, Paredes R; EuroSIDA Study.

Medicine (Baltimore). 2016 Oct;95(40):e5020.

28.

First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.

Poizot-Martin I, Allavena C, Delpierre C, Duvivier C, Obry-Roguet V, Cano CE, Guillouet de Salvador F, Rey D, Dellamonica P, Cheret A, Cuzin L, Katlama C, Cabié A, Hoen B; Dat’AIDS Study Group.

Medicine (Baltimore). 2016 Oct;95(41):e5087.

29.

Hepatitis C treatment initiation in HIV-HCV coinfected patients.

Cotte L, Pugliese P, Valantin MA, Cuzin L, Billaud E, Duvivier C, Naqvi A, Cheret A, Rey D, Pradat P, Poizot-Martin I; Dat’AIDS study Group.

BMC Infect Dis. 2016 Jul 22;16:345. doi: 10.1186/s12879-016-1681-1.

30.

Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].

Michel L, Lions C, Winnock M, Lang JP, Loko MA, Rosenthal E, Marchou B, Valantin MA, Morlat P, Roux P, Sogni P, Spire B, Poizot-Martin I, Lacombe K, Lascoux-Combe C, Duvivier C, Neau D, Dabis F, Salmon-Ceron D, Carrieri MP; ANRS HEPAVIH CO13 study group.

HIV Med. 2016 Nov;17(10):758-765. doi: 10.1111/hiv.12382.

31.

Aortic stiffness aging is influenced by past profound immunodeficiency in HIV-infected individuals: results from the EVAS-HIV (EValuation of Aortic Stiffness in HIV-infected individuals).

Maia-Leite LH, Catez E, Boyd A, Haddour N, Curjol A, Lang S, Nuernberg M, Duvivier C, Desvarieux M, Kirstetter M, Girard PM, Cohen A, Boccara F.

J Hypertens. 2016 Jul;34(7):1338-46. doi: 10.1097/HJH.0000000000000957.

PMID:
27137177
32.

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).

Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, Girard PM; IMEA 040 DATA Study Group.

J Antimicrob Chemother. 2016 Aug;71(8):2252-61. doi: 10.1093/jac/dkw103. Epub 2016 Apr 10.

PMID:
27068399
33.

Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers.

Makinson A, Eymard-Duvernay S, Raffi F, Abgrall S, Bommart S, Zucman D, Valour F, Cheret A, Poizot-Martin I, Duvivier C, Mauboussin JM, Bonnet F, Tattevin P, Reynes J, Le Moing V; ANRS EP48 HIV CHEST study Team.

AIDS. 2016 Feb 20;30(4):573-82. doi: 10.1097/QAD.0000000000000943.

PMID:
26829006
34.

Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.

Allavena C, Katlama C, Cotte L, Roger PM, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabie A, Cheret A, Lahoulou R, Raffi F, Pugliese P; Dat’AIDS Study group.

Infect Dis (Lond). 2016;48(5):392-8. doi: 10.3109/23744235.2015.1133927. Epub 2016 Jan 13.

PMID:
26757613
35.

Identification of Variants of Hepatitis C Virus (HCV) Entry Factors in Patients Highly Exposed to HCV but Remaining Uninfected: An ANRS Case-Control Study.

Fouquet B, Ghosn J, Quertainmont Y, Salmon D, Rioux C, Duvivier C, Delfraissy JF, Misrahi M.

PLoS One. 2015 Nov 16;10(11):e0142698. doi: 10.1371/journal.pone.0142698. eCollection 2015.

36.

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients.

Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin MA, Cuzin L, Billaud E, Cheret A, Rey D, Jacomet C, Duvivier C, Pugliese P, Pradat P, Cotte L; Hepadat'AIDS Study Group.

PLoS One. 2015 Oct 21;10(10):e0141164. doi: 10.1371/journal.pone.0141164. eCollection 2015.

37.

Rapid local adaptation mediates zooplankton community assembly in experimental mesocosms.

Pantel JH, Duvivier C, Meester LD.

Ecol Lett. 2015 Oct;18(10):992-1000. doi: 10.1111/ele.12480. Epub 2015 Aug 6.

PMID:
26251339
38.

Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.

Lê MP, Soulié C, Assoumou L, Valantin MA, Duvivier C, Chas J, Ponscarme D, Marcelin AG, Calvez V, Katlama C, Peytavin G; ROCnRAL ANRS 157 Study Group.

J Antimicrob Chemother. 2015 Aug;70(8):2418-20. doi: 10.1093/jac/dkv113. Epub 2015 Apr 26. No abstract available.

PMID:
25917348
39.

Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.

Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S.

Clin Infect Dis. 2015 May 15;60(10):1521-7. doi: 10.1093/cid/civ124. Epub 2015 Feb 17.

PMID:
25690598
40.

Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region.

Danion F, Belissa E, Peytavin G, Thierry E, Lanternier F, Scemla A, Lortholary O, Delelis O, Avettand-Fenoel V, Duvivier C.

J Antimicrob Chemother. 2015;70(6):1921-3. doi: 10.1093/jac/dkv012. Epub 2015 Feb 10. No abstract available.

PMID:
25670643
41.

Claudin-1 gene variants and susceptibility to hepatitis C infection in HIV-1 infected intravenous drug users (an ANRS case-control study).

Ghosn J, Fouquet B, Quertainmont Y, Salmon D, Sahali S, Rioux C, Duvivier C, Mole M, Delfraissy JF, Misrahi M.

J Med Virol. 2015 Apr;87(4):619-24. doi: 10.1002/jmv.24088. Epub 2015 Jan 21.

PMID:
25611191
42.

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort.

Allavena C, Katlama C, Cotte L, Roger PM, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabié A, Cheret A, Lahoulou R, Raffi F, Pugliese P.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19780. doi: 10.7448/IAS.17.4.19780. eCollection 2014.

43.

Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).

Mary-Krause M, Grabar S, Lièvre L, Abgrall S, Billaud E, Boué F, Boyer L, Cabié A, Cotte L, De Truchis P, Duval X, Duvivier C, Enel P, Gasnault J, Gaud C, Gilquin J, Guiguet M, Katlama C, Khuong-Josses MA, Lacombe JM, Lang S, Lascaux AS, Launay O, Mahamat A, Matheron S, Meynard JL, Pavie J, Pilorgé F, Piroth L, Poizot-Martin I, Potard V, Pradier C, Reynes J, Rouveix E, Selinger-Leneman H, Simon A, Tattevin P, Tissot-Dupont H, Viard JP, Viget N, Costagliola D.

Int J Epidemiol. 2014 Oct;43(5):1425-36. doi: 10.1093/ije/dyu002. Epub 2014 Feb 17.

PMID:
24550249
44.

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.

Katlama C, Assoumou L, Valantin MA, Soulié C, Duvivier C, Chablais L, Kolta S, Pialoux G, Mercié P, Simon A, Costagliola D, Peytavin G, Marcelin AG; ROCnRAL ANRS 157 Study Group.

J Antimicrob Chemother. 2014 Jun;69(6):1648-52. doi: 10.1093/jac/dkt536. Epub 2014 Feb 16.

PMID:
24535278
45.

Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.

Bani-Sadr F, Loko MA, Pambrun E, Winnock M, Carrieri P, Gilbert C, Duvivier C, Bouchaud O, Gervais A, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group.

AIDS. 2014 May 15;28(8):1155-60. doi: 10.1097/QAD.0000000000000218.

PMID:
24499953
46.

Frequency dependence of capnography in anesthetized rabbits.

Ioan I, Demoulin B, Duvivier C, Leblanc AL, Bonabel C, Marchal F, Schweitzer C, Varechova S.

Respir Physiol Neurobiol. 2014 Jan 1;190:14-9. doi: 10.1016/j.resp.2013.09.002. Epub 2013 Sep 12.

PMID:
24035836
47.

A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection.

Bacchus C, Cheret A, Avettand-Fenoël V, Nembot G, Mélard A, Blanc C, Lascoux-Combe C, Slama L, Allegre T, Allavena C, Yazdanpanah Y, Duvivier C, Katlama C, Goujard C, Seksik BC, Leplatois A, Molina JM, Meyer L, Autran B, Rouzioux C; OPTIPRIM ANRS 147 study group.

PLoS One. 2013 May 14;8(5):e64219. doi: 10.1371/journal.pone.0064219. Print 2013.

48.

[Value of the Linton-Nachlas balloon for the management of post-partum hemorrhage: a series of 25 cases].

Florian A, Carles G, Dallah F, Ibrahim N, Alassas N, Duvivier C.

J Gynecol Obstet Biol Reprod (Paris). 2013 Sep;42(5):493-8. doi: 10.1016/j.jgyn.2013.02.008. Epub 2013 Apr 6. French.

49.

Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients.

Zucman D, De Truchis P, Peytavin G, Descamps D, Duvivier C, Tegna L, Weiss L, Delassus JL, Benalycherif A, Landman R.

Scand J Infect Dis. 2013 May;45(5):407-10. doi: 10.3109/00365548.2012.751507. Epub 2013 Mar 11.

PMID:
23477545
50.

Prevalence of CXCR4-tropic viruses in clustered transmission chains at the time of primary HIV-1 infection.

Frange P, Meyer L, Ghosn J, Deveau C, Goujard C, Duvivier C, Tubiana R, Rouzioux C, Chaix ML; ANRS CO6 PRIMO Cohort Study Group.

Clin Microbiol Infect. 2013 May;19(5):E252-5. doi: 10.1111/1469-0691.12127. Epub 2013 Jan 17.

Supplemental Content

Loading ...
Support Center